4//SEC Filing
Pizzuti Dana 4
Accession 0001658247-25-000013
CIK 0001658247other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 4:41 PM ET
Size
9.4 KB
Accession
0001658247-25-000013
Insider Transaction Report
Form 4
Pizzuti Dana
Chief Med and Dev Officer
Transactions
- Exercise/Conversion
Common Stock
2025-10-01$16.89/sh+5,000$84,450→ 71,270 total - Sale
Common Stock
2025-10-01$41.81/sh−5,000$209,050→ 66,270 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-01−5,000→ 79,042 totalExercise: $16.89Exp: 2032-10-10→ Common Stock (5,000 underlying)
Footnotes (4)
- [F1]On September 4, 2025, the Reporting Person filed a Form 4 (the "Prior Form 4") which inadvertently reported that, following the transactions reported in the Prior Form 4, the Reporting Person directly owned 96,270 shares of the Issuer's common stock. In fact, the Reporting Person directly owned 66,270 shares of the Issuer's common stock following the transactions reported in the Prior Form 4.
- [F2]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.
- [F3]The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $41.81 per share. The range of sales prices on the transaction date was $41.34 to $42.16 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
- [F4]The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Documents
Issuer
Crinetics Pharmaceuticals, Inc.
CIK 0001658247
Entity typeother
Related Parties
1- filerCIK 0001948238
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 4:41 PM ET
- Size
- 9.4 KB